Yousif Capital Management LLC Sells 2,906 Shares of Johnson & Johnson $JNJ

Yousif Capital Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 266,405 shares of the company’s stock after selling 2,906 shares during the quarter. Johnson & Johnson makes up about 0.8% of Yousif Capital Management LLC’s holdings, making the stock its 17th biggest holding. Yousif Capital Management LLC’s holdings in Johnson & Johnson were worth $70,528,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth $28,000. Matrix Trust Co grew its stake in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after buying an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $43,000. Polaris Financial Partners purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $56,000. Finally, Bullseye Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $63,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 1.0%

Shares of NYSE:JNJ opened at $266.38 on Tuesday. The firm’s 50 day moving average price is $265.35 and its 200 day moving average price is $245.32. The stock has a market cap of $641.25 billion, a price-to-earnings ratio of 40.36, a price-to-earnings-growth ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter in the previous year, the business posted $2.80 EPS. The firm’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising prostate-cancer data: Experimental drug JNJ-6143 produced tumor-response rates of roughly 69% to 75% in heavily pretreated patients with advanced prostate cancer. The results support further development of the first-in-class RIPTAC drug, although the evidence remains early-stage. What Do Johnson & Johnson Cancer Trial Wins Mean For Its Stock?
• Positive Sentiment: RYBREVANT expansion potential: A subcutaneous RYBREVANT FASPRO combination generated a 77% overall response rate in first-line treatment of advanced head and neck cancer. The findings support the ongoing Phase 3 OrigAMI-5 trial and could broaden the commercial opportunity for a key oncology franchise. RYBREVANT FASPRO Head and Neck Cancer Results
• Positive Sentiment: ERLEADA showed a meaningful benefit: Johnson & Johnson said using ERLEADA before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk localized or locally advanced prostate cancer, potentially supporting broader adoption. ERLEADA Surgical Study Results
• Neutral Sentiment: ETF activity showed net selling of JNJ, but this is generally a short-term trading signal rather than a change in the company’s fundamentals.
• Negative Sentiment: An expected orthopedics merger with Smith & Nephew collapsed over leadership disagreements, removing a potential strategic opportunity. The strong cancer data also comes with clinical and regulatory risks because several programs remain in relatively early development.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. HSBC increased their target price on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research report on Thursday, October 15th. Erste Group Bank lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada lowered their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 64,515 shares of company stock worth $17,271,766 over the last 90 days. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.